{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:30:18Z","timestamp":1787841018452,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10067-024-07027-x","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T06:02:20Z","timestamp":1718344940000},"page":"2391-2402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Upadacitinib for axial spondyloarthritis: a meta-analysis of efficacy and safety"],"prefix":"10.1007","volume":"43","author":[{"given":"HanMing","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoChen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiKun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1129-5485","authenticated-orcid":false,"given":"ZhiYong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenZhe","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"issue":"10089","key":"7027_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D (2017) Axial spondyloarthritis [J]. Lancet (London, England) 390(10089):73\u201384","journal-title":"Lancet (London, England)"},{"issue":"8","key":"7027_CR2","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/ard.2006.064543","volume":"66","author":"B Vander Cruyssen","year":"2007","unstructured":"Vander Cruyssen B, Ribbens C, Boonen A et al (2007) The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice [J]. Ann Rheum Dis 66(8):1072\u20131077","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7027_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection [J]. Ann Rheum Dis 68(6):777\u2013783","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"7027_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41584-019-0309-4","volume":"15","author":"WP Maksymowych","year":"2019","unstructured":"Maksymowych WP (2019) The role of imaging in the diagnosis and management of axial spondyloarthritis [J]. Nat Rev Rheumatol 15(11):657\u2013672","journal-title":"Nat Rev Rheumatol"},{"key":"7027_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fmed.2018.00080","volume":"5","author":"M Laurence","year":"2018","unstructured":"Laurence M, Asquith M, Rosenbaum JT (2018) Spondyloarthritis, acute anterior uveitis, and fungi: updating the Catterall-King hypothesis [J]. Front Med 5:80","journal-title":"Front Med"},{"issue":"4","key":"7027_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41584-022-00761-z","volume":"18","author":"A Danve","year":"2022","unstructured":"Danve A, Deodhar A (2022) Treatment of axial spondyloarthritis: an update [J]. Nat Rev Rheumatol 18(4):205\u2013216","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"7027_CR7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis [J]. Ann Rheum Dis 76(6):978\u2013991","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7027_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M et al (2017) JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects [J]. Drugs 77(5):521\u2013546","journal-title":"Drugs"},{"issue":"10162","key":"7027_CR9","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Baraliakos X, Gensler LS et al (2018) Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial [J]. Lancet (London, England) 392(10162):2378\u20132387","journal-title":"Lancet (London, England)"},{"issue":"8","key":"7027_CR10","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC et al (2017) Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study [J]. Ann Rheum Dis 76(8):1340\u20131347","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"7027_CR11","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H et al (2021) Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study [J]. Ann Rheum Dis 80(8):1004\u20131013","journal-title":"Ann Rheum Dis"},{"key":"7027_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C et al (2018) In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494) [J]. BMC Rheumatol 2:23","journal-title":"BMC Rheumatol"},{"issue":"2","key":"7027_CR13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/jcph.1513","volume":"60","author":"MF Mohamed","year":"2020","unstructured":"Mohamed MF, Beck D, Camp HS et al (2020) Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib [J]. J Clin Pharmacol 60(2):188\u2013197","journal-title":"J Clin Pharmacol"},{"issue":"01","key":"7027_CR14","first-page":"117","volume":"17","author":"L Haining","year":"2017","unstructured":"Haining L, Hao W, Can Y et al (2017) Advanced methods of data extraction for continuous outcomes in meta-analysis [J]. Chin J Evid Based Med 17(01):117\u2013121","journal-title":"Chin J Evid Based Med"},{"issue":"10","key":"7027_CR15","first-page":"Ed000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions [J]. Cochrane Database Syst Rev 10(10):Ed000142","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"7027_CR16","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis [J]. Stat Med 21(11):1539\u20131558","journal-title":"Stat Med"},{"issue":"7109","key":"7027_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test [J]. BMJ (Clin Res Ed) 315(7109):629\u2013634","journal-title":"BMJ (Clin Res Ed)"},{"issue":"1","key":"7027_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13075-023-03027-5","volume":"25","author":"X Baraliakos","year":"2023","unstructured":"Baraliakos X, Ranza R, \u00d6st\u00f6r A et al (2023) Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies [J]. Arthritis Res Ther 25(1):56","journal-title":"Arthritis Res Ther"},{"issue":"10349","key":"7027_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, van den Bosch F, Poddubnyy D et al (2022) Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet (London, England) 400(10349):369\u2013379","journal-title":"Lancet (London, England)"},{"issue":"11","key":"7027_CR20","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","volume":"81","author":"D van der Heijde","year":"2022","unstructured":"van der Heijde D, Baraliakos X, Sieper J et al (2022) Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial [J]. Ann Rheum Dis 81(11):1515\u20131523","journal-title":"Ann Rheum Dis"},{"issue":"10214","key":"7027_CR21","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL et al (2019) Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial [J]. Lancet (London, England) 394(10214):2108\u20132117","journal-title":"Lancet (London, England)"},{"issue":"3","key":"7027_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Lertratanakul A, Anderson JK et al (2021) Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2 [J]. Ann Rheum Dis 80(3):312\u2013320","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"7027_CR23","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Anderson JK, Magrey M et al (2021) Trial of upadacitinib and adalimumab for psoriatic arthritis [J]. N Engl J Med 384(13):1227\u20131239","journal-title":"N Engl J Med"},{"issue":"12","key":"7027_CR24","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41584-019-0294-7","volume":"15","author":"J Sieper","year":"2019","unstructured":"Sieper J, Poddubnyy D, Miossec P (2019) The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis [J]. Nat Rev Rheumatol 15(12):747\u2013757","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"7027_CR25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","volume":"13","author":"G Schett","year":"2017","unstructured":"Schett G, Lories RJ, D\u2019Agostino MA et al (2017) Enthesitis: from pathophysiology to treatment [J]. Nat Rev Rheumatol 13(12):731\u2013741","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"7027_CR26","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","volume":"80","author":"V Navarro-Comp\u00e1n","year":"2021","unstructured":"Navarro-Comp\u00e1n V, Sepriano A, El-Zorkany B et al (2021) Axial spondyloarthritis [J]. Ann Rheum Dis 80(12):1511\u20131521","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7027_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.31138\/mjr.34.2.129","volume":"34","author":"K Klavdianou","year":"2023","unstructured":"Klavdianou K, Papagoras C, Baraliakos X (2023) JAK inhibitors for the treatment of axial spondyloarthritis [J]. Mediterr J Rheumatol 34(2):129\u2013138","journal-title":"Mediterr J Rheumatol"},{"key":"7027_CR28","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.2147\/DDDT.S330413","volume":"16","author":"J Braun","year":"2022","unstructured":"Braun J, Kiltz U, Baraliakos X (2022) Management of axial spondyloarthritis - insights into upadacitinib [J]. Drug Des Dev Ther 16:3609\u20133620","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"7027_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca R, Heslinga SC, Rollefstad S et al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update [J]. Ann Rheum Dis 76(1):17\u201328","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"7027_CR30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis [J]. N Engl J Med 386(4):316\u2013326","journal-title":"N Engl J Med"},{"key":"7027_CR31","doi-asserted-by":"publisher","first-page":"106359","DOI":"10.1016\/j.phrs.2022.106359","volume":"183","author":"M Benucci","year":"2022","unstructured":"Benucci M, Damiani A, Infantino M et al (2022) Cardiovascular safety, cancer and Jak-inhibitors: differences to be highlighted [J]. Pharmacol Res 183:106359","journal-title":"Pharmacol Res"},{"issue":"1","key":"7027_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update [J]. Ann Rheum Dis 82(1):3\u201318","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7027_CR33","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","volume":"58","author":"EH Choy","year":"2019","unstructured":"Choy EH (2019) Clinical significance of Janus Kinase inhibitor selectivity [J]. Rheumatology (Oxford) 58(6):953\u2013962","journal-title":"Rheumatology (Oxford)"},{"issue":"10341","key":"7027_CR34","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W et al (2022) Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials [J]. Lancet (London, England) 399(10341):2113\u20132128","journal-title":"Lancet (London, England)"},{"issue":"21","key":"7027_CR35","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP et al (2023) Upadacitinib induction and maintenance therapy for Crohn\u2019s disease [J]. N Engl J Med 388(21):1966\u20131980","journal-title":"N Engl J Med"},{"issue":"16","key":"7027_CR36","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL et al (2020) Trial of upadacitinib or abatacept in rheumatoid arthritis [J]. N Engl J Med 383(16):1511\u20131521","journal-title":"N Engl J Med"},{"key":"7027_CR37","doi-asserted-by":"publisher","unstructured":"Zimba O, Kocyigit BF, Korkosz M (2024) Diagnosis, monitoring, and management of axial spondyloarthritis. Rheumatol Int. https:\/\/doi.org\/10.1007\/s00296-024-05615-3","DOI":"10.1007\/s00296-024-05615-3"},{"issue":"8","key":"7027_CR38","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/ard.2010.145995","volume":"70","author":"D Poddubnyy","year":"2011","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H et al (2011) Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 70(8):1369\u20131374","journal-title":"Ann Rheum Dis"},{"key":"7027_CR39","doi-asserted-by":"crossref","unstructured":"Watad A, Bridgewood C, Russell T et al (2018) The early phases of ankylosing spondylitis: emerging insights from clinical and basic science. Front Immunol 9:2668","DOI":"10.3389\/fimmu.2018.02668"},{"key":"7027_CR40","doi-asserted-by":"publisher","unstructured":"Maksymowych W, Hadsbjerg AEFEF, \u00d8stergaard M, et al (2024) Validation of SPARCC MRI-RETIC e-tools for increasing scoring proficiency of MRI sacroiliac joint lesions in axial spondyloarthritis [J]. RMD open, 2024 10(1):e003923. https:\/\/doi.org\/10.1136\/rmdopen-2023-003923","DOI":"10.1136\/rmdopen-2023-003923"},{"issue":"7","key":"7027_CR41","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2014-206971","volume":"74","author":"P Mandl","year":"2015","unstructured":"Mandl P, Navarro-Comp\u00e1n V, Terslev L et al (2015) EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice [J]. Ann Rheum Dis 74(7):1327\u20131339","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7027_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13075-018-1565-4","volume":"20","author":"M Haroon","year":"2018","unstructured":"Haroon M, Ahmad M, Baig MN et al (2018) Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study [J]. Arthritis Res Ther 20(1):73","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"7027_CR43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/BOR.0000000000000609","volume":"31","author":"V Chandran","year":"2019","unstructured":"Chandran V (2019) Psoriatic spondylitis or ankylosing spondylitis with psoriasis: same or different? [J]. Curr Opin Rheumatol 31(4):329\u2013334","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"7027_CR44","first-page":"270","volume":"35","author":"M Haroon","year":"2017","unstructured":"Haroon M, Winchester R, Giles JT et al (2017) Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis [J]. Clin Exp Rheumatol 35(2):270\u2013276","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"7027_CR45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13075-015-0640-3","volume":"17","author":"O Fitzgerald","year":"2015","unstructured":"Fitzgerald O, Haroon M, Giles JT et al (2015) Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype [J]. Arthritis Res Ther 17(1):115","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"7027_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/annrheumdis-2014-205461","volume":"75","author":"M Haroon","year":"2016","unstructured":"Haroon M, Winchester R, Giles JT et al (2016) Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype [J]. Ann Rheum Dis 75(1):155\u2013162","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"7027_CR47","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/rheumatology\/kex174","volume":"56","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Dougados M, Landew\u00e9 R et al (2017) Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA [J]. Rheumatology (Oxford) 56(9):1498\u20131509","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07027-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07027-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07027-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T12:16:52Z","timestamp":1721823412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07027-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7027"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07027-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"assertion":[{"value":"8 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}